NASDAQ:CLVS »

• 
  Company News » Clovis Oncology’s Rociletinib (CO-1686) Phase 2 Study Results Demonstrate Consistent and Promising Clinical Activity and Disease Control in Very Advanced Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  Business Wire - May 31, 2015, 13:01 GMT

  Clovis Oncology (NASDAQ:CLVS) announced today updated findings from its Phase 2 clinical study of rociletinib (CO-1686), the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations, as well as the dominant resistance mutation

  Read full story »
• 
  Company News » Clovis Oncology’s Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity, in Both BRCA-mutant and BRCA-like Patients, Together Comprising Approximately 60 Percent of Patients

  Business Wire - May 30, 2015, 18:16 GMT

  Clovis Oncology (NASDAQ:CLVS) today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company’s investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond

  Read full story »
• 
  Company News » Clovis Oncology Announces Data Presentations at 2015 ASCO Annual Meeting

  Business Wire - May 13, 2015, 21:10 GMT

  Clovis Oncology (NASDAQ:CLVS) today announced that two oral presentations and six poster sessions highlighting updated results and trial designs from clinical studies of the companys three compounds in advanced clinical development are being presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29-June 2, 2015 in Chicago.

  Read full story »
• 
  Company News » Clovis Oncology Announces First Quarter 2015 Operating Results

  Business Wire - May 6, 2015, 20:10 GMT

  Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter ended March 31, 2015, and provided an update on the Companys clinical development programs for 2015. 2015 is proving to be a very exciting and important year for us, as we are preparing our near-term regulatory submissions seeking approval in the U.S. and E.U. for

  Read full story »
• 
  Company News » Clovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on May 6

  Business Wire - April 23, 2015, 20:03 GMT

  Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call

  Read full story »
• 
  Company News » Clovis Oncology Receives Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations)

  Business Wire - April 6, 2015, 20:03 GMT

  Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA (gBRCA)

  Read full story »
• 
  Company News » Clovis Oncology Announces 2014 Operating Results

  Business Wire - February 25, 2015, 21:02 GMT

  Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2014, and provided an update on the Companys clinical development programs for 2015. We believe that 2015 will be a transformative year for us, as we prepare to submit our NDA and MAA for rociletinib in advanced EGFR-mutant lung cancer

  Read full story »
• 
  Company News » Clovis Oncology to Announce Fourth Quarter/Year-End 2014 Financial Results and Host Webcast Conference Call on February 25

  Business Wire - February 17, 2015, 23:12 GMT

  Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter/year-end 2014 financial results on Wednesday, February 25, 2015, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call

  Read full story »
• 
  Company News » Clovis Oncology to Present at the 2015 Leerink Global Healthcare Conference

  Business Wire - February 4, 2015, 13:05 GMT

  Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company’s executive vice president and CFO, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, at 1:25 p.m. EST. The conference is being held at the Waldorf Astoria in New York City. A live webcast of the corporate presentation

  Read full story »
• 
  Company News » Clovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference

  Business Wire - January 5, 2015, 23:31 GMT

  Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of

  Read full story »